Tag: esketamine market

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Esketamine Market Today And What Is Its Future Size?

The size of the esketamine market has robustly expanded in the past years. The market will see an increase from $1.37 billion in 2024 to $1.51 billion in 2025, with a compound annual growth rate (CAGR) of 9.9%. The escalation witnessed during the historic period is due to a higher patient count, growing instances of mental health complications globally, enhanced comprehension of the disease condition, increasing requirement for cutting-edge treatment choices, and supportive regulatory permissions.

Expectation for the esketamine market size to witness a substantial surge in the coming years is high, with forecasts suggesting an expansion to “$2.26 billion by 2029, with a 10.7% compound annual growth rate (CAGR). This predicted escalation during the forecast period is attributed to the growing incidences of treatment-resistant depression, the escalation in research and development investment trends, the demand for intelligent healthcare infrastructure, the rising popularity of telehealth services, and the increasing adoption of esketamine as an effective treatment method. Enhancements in the forecast period are to include biotech firm partnerships with mental health organizations, the integration of robotics into healthcare applications, the prioritization of personalized medicine approaches, the use of sensor-based devices, and the probability of combination therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

What External And Internal Drivers Are Influencing The Esketamine Market?

The escalating incidences of Treatment-Resistant Depression (TRD), which is not responsive to at least two different antidepressant medications given in the correct dosage and period, are likely to surge the expansion of the esketamine market in the future years. The growth of TRD has been attributed to the insufficient effectiveness of existing antidepressants, resulting in extended and repeated depressive stages. Esketamine assists TRD patients by offering a quick-acting solution that targets NMDA receptors, providing aid to those who don’t respond to conventional antidepressants. For instance, data from the National Institute of Mental Health (NIMH), a US federal organization, revealed that around 30% of individuals in the U.S. suffering from major depressive disorder in 2023 show resistance to standard treatments. Consequently, the escalating occurrence of treatment-resistant depression is triggering the expansion of the esketamine market.

Which Segmentation Factors Are Critical In The Esketamine Market Analysis?

The esketamine market covered in this report is segmented –

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients

4) By Application: General Anesthetic, Treatment-Resistant Depression

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

What Are The Dominant Trends Currently Seen In The Esketamine Market?

Leading entities in the esketamine market are prioritizing the creation of progressive treatment options, like monotherapy, to augment the relief from depressive symptoms beyond what can be achieved with placebos. Monotherapy is the technique of tackling a disease or a medical condition with a solitary drug or treatment, eschewing the blend of multiple therapies. In the case of Johnson & Johnson, an American pharmaceutical magnate, in January 2025, it unveiled that the U.S. Food and Drug Administration (FDA) sanctioned SPRAVATO (esketamine) for use as the sole monotherapy for adults with treatment-resistant depression (TRD). This approval, backed by clinical trial evidence, indicated that SPRAVATO can swiftly lessen depressive symptoms, with substantial progress noted within a day. This development paves the way for critical treatment alternatives for roughly 30% of people who do not respond well to conventional antidepressants, thereby sidelining the necessity for simultaneous oral medications. Despite SPRAVATO having a commendable safety record, it is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) to counter possible adverse effects. This landmark achievement signals a pivotal leap forward in the treatment of TRD, sparking newfound optimism for enhanced patient recovery.

Who Are The Dominant Players In The Esketamine Market Today?

Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Esketamine Market?

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Outlook for the Vitamin Tonics Market Heading Into 2029?#_x000D_

In recent times, there has been significant growth in the esketamine market size. The market is predicted to expand from $1.37 billion in 2024 to $1.51 billion in 2025, with a compound annual growth rate (CAGR) of 9.9%. The growth experienced in the historic period can be credited to a rise in the patient count, increasing world prevalence of mental health illnesses, enhanced consciousness about the condition, increased demand for innovative treatment alternatives, and positive regulatory sanctions._x000D_

_x000D_

In the upcoming years, the esketamine market size is predicted to exhibit a rapid expansion, reaching “$2.26 billion in 2029 with a compound annual growth rate (CAGR) of 10.7%. The accelerated growth during the forecast period is largely due to factors such as the rising occurrence of treatment-resistant depression, escalating investments in R&D activities, an amplified demand for intelligent healthcare infrastructure, the expanding popularity of telehealth services, and increased recognition of esketamine as a potent treatment. The forecast period also anticipates significant trends such as collaborations between biotech companies and mental health organizations, the introduction of robotics in healthcare, the implementation of personalized medicine approaches, the use of sensor-based devices, and the potential of combination therapies._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp_x000D_

_x000D_

#Which Factors Are Pushing The Vitamin Tonics Market Forward?#_x000D_

The vitamin tonics market is projected to expand due to the rising prevalence of chronic diseases. Chronic ailments, typically lasting three months or more, necessitate continual medical intervention and often restrict daily activities. Vitamin tonics play a crucial role in preventing and treating numerous deficiency-associated conditions in chronic diseases, including rickets, osteomalacia, angular stomatitis, and anemia. A study published in the Journal of Hematology and Oncology, a US-based oncology journal, prophesies that the population of people in the United States aged 50 years and older suffering from at least one chronic disease will surge by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Consequently, the escalating number of chronic diseases can be deemed a driving force for the growth of the vitamin tonics market._x000D_

_x000D_

_x000D_

The esketamine market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types_x000D_

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders_x000D_

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients_x000D_

4) By Application: General Anesthetic, Treatment-Resistant Depression_x000D_

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets _x000D_

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection_x000D_

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray_x000D_

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy_x000D_

_x000D_

#What Future Market Trends Are Projected For The Vitamin Tonics Industry?#_x000D_

Key players in the esketamine market are making strides to create cutting-edge treatments like monotherapy, aiming to surpass the impact of placebo on depressive symptoms. Monotherapy implies using a solitary medication or treatment method, eliminating the need for combination of multiple therapies. For instance, in the first month of 2025, the U.S. Food and Drug Administration (FDA) gave its approval to Johnson & Johnson, a recognized pharmaceutical company in the U.S., for the usage of SPRAVATO (esketamine) as the pioneering and unique monotherapy for adults grappling with treatment-resistant depression (TRD). Confirmations from clinical trials led to this approval, demonstrating SPRAVATO has the power to quickly reduce depressive symptoms, with notable improvements seen within a day. This major development provides a vital solution for the approximate 30% of people who are insusceptible to conventional antidepressants, thereby excluding the requirement for simultaneous oral medications. Although SPRAVATO has a satisfactory safety track record, it is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) to counteract potential adverse reactions. This achievement signifies a tremendous leap forward in TRD therapy, shedding new light on the prospect of enhanced patient results._x000D_

_x000D_

#Which Organizations Are Driving Progress In The Vitamin Tonics Industry?#_x000D_

Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc. _x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report_x000D_

_x000D_

#Which Region Is Expected To Experience The Highest Growth In The Vitamin Tonics Industry?#_x000D_

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Esketamine Market Growth Performance Trended Historically, And What Lies Ahead?#_x000D_

In recent times, the esketamine market has experienced significant growth. The market is projected to increase from $1.37 billion in 2024 to $1.51 billion in 2025, with a compound annual growth rate (CAGR) of 9.9%. Several factors contribute to this growth during the historic period, including a surge in patient numbers, escalating global mental health issues, improved disease awareness levels, a rising demand for new therapeutic treatments, and positive regulatory authorizations._x000D_

_x000D_

Anticipations are high for the esketamine market as it is projected to witness substantial growth in the coming years. By 2029, it is estimated to reach a value of $2.26 billion, expanding at a compound annual growth rate (CAGR) of 10.7%. This growth through the forecast period is due to several factors such as the rising incidence of treatment-resistant depression, surge in funding for research and developmental activities, increasing demand for intelligent healthcare infrastructure, growing uptake of telehealth services, and more acceptance of esketamine as a viable treatment measure. The forecast period is also expected to see certain trends like collaborations between biotech companies and mental health agencies, the use of robotics in healthcare, application of personalized medicine approaches, deployment of sensor-based devices, and feasibility of combination treatments._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp_x000D_

_x000D_

#Which Factors and External Forces Are Driving Demand in the Esketamine Market?#_x000D_

The surge in the occurrence of treatment-resistant depression (TRD) is projected to drive the expansion of the esketamine market in future years. TRD is described as depression, unaffected after the implementation of at least two varied antidepressant medications at rightful doses for an adequate time span. The growth in TRD cases can be attributed to the insufficient efficacy of conventional antidepressants, contributing to extensive and repetitive depressive instances. Esketamine aids TRD by supplying a rapid-acting process that focuses on the NMDA receptors, giving respite for patients unresponsive to standard antidepressants. For example, the National Institute of Mental Health (NIMH), a federal agency in the U.S., in September 2023, disclosed that around 30% of people having major depressive disorder in the U.S. are unresponsive to standard treatments in 2023. Hence, the escalating prevalence of treatment-resistant depression is fuelling the development of the esketamine market._x000D_

_x000D_

#Which Segments in the Esketamine Offer the Most Growth?#_x000D_

The esketamine market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types_x000D_

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders_x000D_

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients_x000D_

4) By Application: General Anesthetic, Treatment-Resistant Depression_x000D_

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets _x000D_

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection_x000D_

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray_x000D_

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Esketamine Market?# Market?#_x000D_

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Cutting-Edge Market Trends Are Expected to Drive theEsketamine Market’s Growth?#_x000D_

Significant market players in the esketamine sector are focusing their efforts on creating superior treatment options such as monotherapy in order to offer an improvement over what is achieved with placebos in managing depression symptoms. Monotherapy involves the use of just one drug or treatment in controlling a disease or medical condition rather than incorporating several therapies. A prime example was seen in January 2025, when US-based pharmaceutical firm, Johnson & Johnson, revealed that SPRAVATO (esketamine), had received approval from the US Food and Drug Administration (FDA) as the sole monotherapy for adults suffering from treatment-resistant depression (TRD). Backed by clinical trials, the approval showed SPRAVATO’s swift calming effect on depressive symptoms, with notable improvement seen within the first 24 hours. This development presents a crucial option for an approximate 30% of people not affected by conventional antidepressants, thus eliminating the requirement for simultaneous oral medication. Although SPRAVATO has an acceptable safety record, it is given under a Risk Evaluation and Mitigation Strategy (REMS) to handle potential side effects. This achievement represents a substantial progression in managing TRD, providing fresh prospects for enhanced patient recovery outcomes._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Esketamine Market?#_x000D_

Esketamine refers to a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is used for treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23393_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Esketamine Market Growth in 2025?

In the past few years, there has been a swift expansion in the esketamine market size. The market is projected to surge from $1.37 billion in 2024 to $1.52 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.2%. This augmentation during the historic period is primarily due to an uptick in patient numbers, a rising global prevalence of mental health disorders, enhanced disease state awareness, growing demand for innovative treatment alternatives, and positive regulatory approvals.

What Is the Forecast for the Esketamine Market Size Through 2029?

The market size of esketamine is poised for notable acceleration in the years to come, expected to reach $2.31 billion by 2029, with a compound annual growth rate (CAGR) of 11.0%. Factors that will fuel the market growth during the forecast period include the rising cases of treatment-resistant depression, amplified focus on research and development initiatives, the need for smart healthcare frameworks, the propelling incline towards telehealth services, and the mounting recognition of esketamine as a potent treatment method. The forecast period will also see prominent trends such as collaborations between biotech enterprises and mental health associations, the application of robotics in healthcare, personalized treatment approaches, sensor-driven devices, and the opportunity for combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

What are the Key Market Players in Esketamine Market and How They’re Evolving?

Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.

What Are the Primary Growth Drivers in the Esketamine Market?

The escalating occurrence of treatment-resistant depression (TRD) is projected to fuel the expansion of the esketamine market in the forthcoming years. TRD characterizes a form of depression that does not exhibit enhancement after the consumption of at least two distinct antidepressant medications at correct doses over an adequate period. The surge in TRD incidences is due to the diminished effectiveness of traditional antidepressants which results in protracted and recurring depressive episodes. Esketamine aids in alleviating TRD through a rapid action mechanism that targets NMDA receptors, offering solace for patients who are unresponsive to classical antidepressants. For instance, the U.S.-based federal body, National Institute of Mental Health reported in September 2023, a resistance to standard treatments amongst about 30% of individuals suffering from major depressive disorder in the U.S. in 2023. Thus, the escalating prevalence of treatment-resistant depression accelerates the growth of the esketamine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

What Are the Leading Segments in the Global Esketamine Industry?

The esketamine market covered in this report is segmented –

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients

4) By Application: General Anesthetic, Treatment-Resistant Depression

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

What Are the Key Market Trends in the Esketamine Industry?

Leading players in the esketamine market are concentrating their efforts on creating innovative treatment methods such as monotherapy, aiming to provide better relief from depressive symptoms than what a placebo can provide. Monotherapy involves using just one specific drug or treatment regime for managing a disease or health condition, as opposed to using a combination of several treatments. A case in point is Johnson & Johnson, an American pharmaceutical firm, which announced in January 2025 that the U.S. Food and Drug Administration (FDA) had endorsed SPRAVATO (esketamine) as the exclusive monotherapy for adults struggling with treatment-resistant depression (TRD). Strongly backed by clinical research, this endorsement proved that SPRAVATO holds the potential for speeding up the alleviation of depressive symptoms, with noticeable improvements seen within 24 hours. This pioneering development brings a much-needed solution for around 30% of people who do not achieve the desired results from conventional antidepressants, effectively doing away with parallel oral medication. Although SPRAVATO has a positive safety record, it must be dispensed under a Risk Evaluation and Mitigation Strategy (REMS) to safeguard against any possible side effects. This achievement points to a crucial leap forward in the treatment of TRD, opening up the likelihood of enhanced patient results.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

What Is the Regional Outlook for the Esketamine Market?

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23393

This Report Delivers Insight On:

1. How big is the esketamine market, and how is it changing globally?

2. Who are the major companies in the esketamine market, and how are they performing?

3. What are the key opportunities and risks in the esketamine market right now?

4. Which products or customer segments are growing the most in the esketamine market?

5. What factors are helping or slowing down the growth of the esketamine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!

What Are the Key Milestones in the Esketamine Market’s Growth Trajectory From 2025 To 2034?

The growth of the esketamine market has been swift in the past few years. It is projected to expand from a worth of $1.37 billion in 2024 to a value of $1.52 billion in 2025, at a compound annual growth rate (CAGR) of 11.2%. This growth during the historic period could be credited to a rise in the patient count, a global increase in the incidence of mental health disorders, improved awareness about the disease condition, a growing demand for new treatment possibilities, and advantageous regulatory authorizations.

It is projected that the esketamine market will experience a swift expansion in the upcoming years, reaching an estimated value of $2.31 billion in 2029, growing at an 11.0% compound annual growth rate (CAGR). This growth can be credited to factors such as a higher occurrence of treatment-resistant depression, a boost in investment for research and development initiatives, the desire for intelligent healthcare infrastructure, the rising popularity of telehealth solutions, and the escalating recognition of esketamine as a potent cure. Key trends per the forecast include collaborations between biopharmaceutical firms and mental health agencies, the utilization of robots in healthcare, personalized treatment approaches, the emergence of sensor-based gadgets, and the feasibility of combination treatments.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Primay Drivers Are Accelerating Growth in the Esketamine Market?

The rise in cases of treatment-resistant depression (TRD) is anticipated to fuel the expansion of the esketamine market in the future years. TRD is characterized by unresponsive depression after undertaking at least two different antidepressant medications with the right dosages for the appropriate length of time. The surge in TRD cases can be attributed to the insufficient effectiveness of standard antidepressants, resulting in sustained and recurrent depressive episodes. Esketamine assists in managing TRD through a quick-response mechanism that focuses on NMDA receptors, providing solace to patients who are unresponsive to traditional antidepressants. For example, the National Institute of Mental Health (NIMH), a US federal agency, revealed that approximately 30% of US individuals dealing with major depressive disorder were unresponsive to standard treatments in 2023. Consequently, the escalating incidence of treatment-resistant depression is propelling the growth of the esketamine market.

Which Primary Segments of the Esketamine Market Are Driving Growth and Industry Transformations?

The esketamine market covered in this report is segmented –

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients

4) By Application: General Anesthetic, Treatment-Resistant Depression

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

Which Regions Are Key Players in the Growth of the Esketamine Market?

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive the Esketamine Market’s Growth?

Leading players in the esketamine market are steering their efforts towards creating better treatment options like monotherapy, to exceed what a placebo can provide in terms of symptom relief for depression. Monotherapy only involves a single type of treatment or drug for tackling a disease or medical condition instead of implementing multiple therapies in synchrony. For example, in January 2025, U.S based pharmaceutical giant, Johnson & Johnson, declared that SPRAVATO (esketamine) had been given the official nod by U.S. Food and Drug Administration (FDA) as the exclusive monotherapy for adults who are resistant to the standard treatments available for depression also known as TRD. The approval, backed by clinical trials, proved that SPRAVATO could quickly alleviate symptoms of depression, with substantial improvements noticed in under a day’s time. This monumental innovation caters to nearly 30% of people who remain unresponsive to traditional antidepressants thus completely replacing the need for additional oral medication. Despite its promising safety credentials, SPRAVATO is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) to handle any potential side-effects. This landmark achievement underscores an enormous leap in the field of TRD treatment, infusing fresh optimism for enhanced patient recovery.

View the full report here:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

What Parameters Are Used to Define the Esketamine Market?

Esketamine refers to a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is used for treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23393

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model